Skip to main content

Table 2 Changes of miRNA expression in BJAB, OCI-LY3 and SU-DHL-6 cells after incubation with the c-MYC-inhibitor (5 µM), LY294002 (5 µM), Rapamycin (500 nM), PD98059 (10 µM) and SB203580 (10 µM) for 24 h

From: Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability

  miR21 miR23a miR133a miR133b miR138-1 miR143
BJAB cells
c-MYC-inh.
ΔΔCT 1.78 ± 0.13 ↓ 0.16 ± 0.11 0.80 ± 0.14 ↓ −0.89 ± 0.14 ↑ −1.68 ± 0.17 ↑ −0.12 ± 0.14
Fold of untreated 0.29 (0.27–0.32)* 0.90 (0.83–0.97) 0.57 (0.54–0.61)* 1.85 (1.68–2.04)* 3.20 (2.85–3.61)* 1.09 (0.99–1.20)
LY294002
ΔΔCT 1.06 ± 0.18 ↓ 0.21 ± 0.19 1.02 ± 0.20 ↓ 0.52 ± 0.12 ↑ −0.54 ± 0.09 ↑ 0.06 ± 0.11
Fold of untreated 0.48 (0.42–0.54)* 0.86 (0.76–0.99) 0.49 (0.43–0.57)* 1.43 (1.32–1.56)* 1.45 (1.37–1.55)* 0.96 (0.89–1.04)
Rapamycin
ΔΔCT 1.28 ± 0.08 ↓ 0.27 ± 0.24 −0.64 ± 0.15 ↑ −0.86 ± 0.12 ↑ −0.53 ± 0.11 ↑ 0.21 ± 0.20
Fold of untreated 0.41 (0.39–0.44)* 0.83 (0.70–0.98) 1.56 (1.40–1.73)* 1.82 (1.67–1.97)* 1.44 (1.34–1.56)* 0.86 (0.75–0.99)
PD98059
ΔΔCT 0.03 ± 0.08 −0.04 ± 0.07 −0.65 ± 0.12 ↑ −0.60 ± 0.15 ↑ −1.51 ± 0.14 ↑ 0.05 ± 0.10
Fold of untreated 0.98 (0.93–1.04) 1.03 (0.98–1.08) 1.57 (1.44–1.71)* 1.52 (1.37–1.68)* 2.85 (2.58–3.14)* 0.97 (0.90–1.04)
SB203580
ΔΔCT −0.04 ± 0.13 −0.01 ± 0.11 0.03 ± 0.07 −0.01 ± 0.07 −0.05 ± 0.12 0.06 ± 0.09
Fold of untreated 1.03 (0.94–1.13) 1.01 (0.93–1.09) 0.98 (0.93–1.03) 1.01 (0.96–1.06) 1.04 (0.95–1.13) 0.96 (0.90–1.02)
OCI-LY3 cells
c-MYC-inh.
ΔΔCT 1.20 ± 0.15 ↓ 0.19 ± 0.17 0.83 ± 0.12 ↓ −0.70 ± 0.13 ↑ −1.47 ± 0.16 ↑ −0.06 ± 0.11
Fold of untreated 0.44 (0.39–0.48)* 0.88 (0.78–0.99) 0.56 (0.52–0.61)* 1.62 (1.48–1.78)* 2.77 (2.48–3.10)* 1.04 (0.97–1.13)
LY294002
ΔΔCT 0.76 ± 0.14 ↓ 0.05 ± 0.09 0.61 ± 0.14 ↓ −0.77 ± 0.13 ↑ −0.84 ± 0.18 ↑ 0.13 ± 0.12
Fold of untreated 0.59 (0.54–0.65)* 0.97 (0.91–1.03) 0.66 (0.59–0.72)* 1.71 (1.56–1.87)* 1.79 (1.58–2.03)* 0.91 (0.84–0.99)
Rapamycin
ΔΔCT 1.45 ± 0.17 ↓ 0.20 ± 0.18 −0.80 ± 0.16 ↑ −0.60 ± 0.10 ↑ −0.93 ± 0.12 ↑ −0.02 ± 0.06
Fold of untreated 0.37 (0.33–0.41)* 0.87 (0.77–0.99) 1.74 (1.56–1.95)* 1.52 (1.40–1.64)* 1.91 (1.75–2.07)* 1.01 (0.97–1.06)
PD98059
ΔΔCT −0.04 ± 0.08 0.26 ± 0.15 −0.77 ± 0.13 ↑ −0.53 ± 0.13 ↑ 0.06 ± 0.10 −0.14 ± 0.16
Fold of untreated 1.03 (0.97–1.09) 0.90 (0.81–0.99) 1.71 (1.56–1.87)* 1.44 (1.32–1.58)* 0.96 (0.90–1.03) 1.10 (0.99–1.23)
SB203580
ΔΔCT 0.05 ± 0.08 −0.05 ± 0.07 −0.17 ± 0.15 0.09 ± 0.13 0.00 ± 0.09 −0.14 ± 0.13
Fold of untreated 0.97 (0.91–1.02) 1.04 (0.99–1.09) 0.89 (0.80–0.99) 0.94 (0.86–1.03) 1.00 (0.94–1.06) 1.10 (1.01–1.21)
SU-DHL-6 cells
c-MYC-inh.
ΔΔCT 0.68 ± 0.13 ↓ −0.03 ± 0.07 ne −0.99 ± 0.17 ↑ 0.08 ± 0.11 ne
Fold of untreated 0.62 (0.57–0.68)* 1.02 (0.97–1.07) 1.99 (1.77–2.23)* 0.95 (0.81–1.02)
LY294002
ΔΔCT 0.12 ± 0.20 −0.21 ± 0.24 ne 0.73 ± 0.10 ↓ −0.03 ± 0.13 ne
Fold of untreated 0.92 (0.80–1.06) 1.16 (0.98–1.37) 0.60 (0.56–0.65)* 1.02 (0.93–1.12)
Rapamycin
ΔΔCT 1.14 ± 0.14 ↓ 0.05 ± 0.07 ne −0.77 ± 0.13 ↑ −0.07 ± 0.11 ne
Fold of untreated 0.45 (0.41–0.50)* 0.97 (0.92–1.01) 1.71 (1.56–1.87)* 1.05 (0.97–1.13)
PD98059
ΔΔCT −0.08 ± 0.14 0.06 ± 0.07 ne −0.07 ± 0.11 −0.01 ± 0.06 ne
Fold of untreated 1.06 (0.96–1.16) 0.96 (0.91–1.01) 1.05 (0.97–1.13) 1.01 (0.97–1.05)
SB203580
ΔΔCT −0.10 ± 0.09 −0.06 ± 0.10 ne 0.08 ± 0.08 0.03 ± 0.12 ne
Fold of untreated 1.07 (1.01–1.14) 1.04 (0.97–1.12) 0.95 (0.90–1.00) 0.98 (0.90–1.06)
  1. ΔΔCT values referred to changes of miRNA levels corrected to expression of U6 miRNA; changes of expression values represent percent of control, mean ± standard deviation from threefold determinations
  2. * and arrows indicate significant changes (p < 0.05, Mann–Whitney test)
  3. ne not expressed